Luteal Phase Defect
Conditions
Keywords
Frozen embryo transfer, endometrial preparation, artificial cycle, progesterone
Brief summary
This study aims to compare the efficacy, in terms of progesterone levels and clinical outcomes, of two different presentations of micronized vaginal progesterone (400 mg vs. 200 mg) used in endometrial preparation in artificial cycle (AC) for embryo transfer. This is a non-inferiority, retrospective case-control study, with at least 200 cycles analyzed (at least 100 per arm) and the primary outcome is the serum progesterone level on the day of the embryo transfer.
Interventions
DRUGVaginally administered progesterone
The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
Sponsors
Instituto Bernabeu
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with primary or secondary infertility undergoing endometrial preparation for an embryo transfer using standard doses of oral or transdermal estrogens. * Age between 18 and 50 years. * Normal uterine cavity verified by imaging techniques. * Serum progesterone documented on the day of embryo transfer.
Exclusion criteria
* Patients with a history of endometritis. * Patients diagnosed with Asherman's syndrome. * Patients with a different supplementation regimen or doses than those of the study groups.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum progesterone level | On the day of embryo transfer |
Secondary
| Measure | Time frame |
|---|---|
| Need for additional progesterone supplementation | assessed on the day of the embryo transfer |
| Clinical results (ongoing pregnancy and miscarriage rate) | assessed on the day of the pregnancy test and during the pregnancy evolution |
Countries
Spain
Outcome results
None listed